James R. Seibold, M.D.

James R. Seibold, M.D., is the Principal Member of Scleroderma Research Consultants, LLC which was founded in 2010 to foster advances in care, education and research for persons with scleroderma and related disorders.

Dr. Seibold was most recently Professor of Medicine and Chief of the Division of Rheumatology at the University of Connecticut Health Center in Farmington, Connecticut, USA. He had previously served on the faculty of the University of Michigan from 2004-2010 as the Marvin and Betty Danto Research Professor of Connective Tissue Research and Professor of Internal Medicine in the Division of Rheumatology and as the founding Director of the University of Michigan Scleroderma Program.  He joined the faculty at Michigan in August of 2004 after 24 years at the University of Medicine and Dentistry of New Jersey–Robert Wood Johnson Medical School in New Brunswick, NJ. He served as Chief of the Division of Rheumatology; Director of the Clinical Research Center; and Chair of the Department of Clinical Pharmacology during which he occupied the William H. Conzen Chair of Clinical Pharmacology.

The author of more than 300 scientific publications, Dr. Seibold has served on the editorial boards of both Arthritis & Rheumatism and the Annals of Rheumatic Diseases, and as editor of the scleroderma section of the Yearbook of Rheumatology, Arthritis and Musculoskeletal Disease and Editor-in-Chief of Scleroderma Care and Research. He is currently an Editor of Scleroderma Care and Research and on the Editorial Boards of Clinical and Experimental Rheumatology and the International Journal of Rheumatology.

His major research interests include systemic sclerosis, Raynaud’s phenomenon, interstitial lung disease, pulmonary hypertension, clinical trial design, and drug development in rheumatology. Dr. Seibold has led or been a key participant in nearly every major interventional trial of scleroderma since 1980 and currently serves as the Lead International Investigator on DETECT, a series of studies of oral treprostinil for digital ulcers and the Scleroderma QuERI.

Dr. Seibold has been cited in The Best Doctors in America continuously since the first edition in 1994 and has won numerous awards, including the Arthritis Foundation’s Physician of the Year. He is the founder and a past President of the Scleroderma Clinical Trials Consortium and active in several patient organizations, including the Pulmonary Hypertension Association, the Scleroderma Research Foundation, and serves as Chair of the Medical Advisory Board of the International Scleroderma Network.

Dr. Seibold received his undergraduate degree in biochemistry from Louisiana State University in Baton Rouge, LA, and his medical degree from SUNY at Stony Brook School of Medicine in Stony Brook, NY. He completed postdoctoral training as an intern and resident in internal medicine at Long Island Jewish-Hillside Medical Center in New Hyde Park, NY, and a fellowship at the Division of Rheumatology and Clinical Immunology at the University of Pittsburgh School of Medicine in Pittsburgh, PA. He is a Fellow of the American College of Rheumatology and the American College of Physicians.